Modulation of Human Immune Cells by Propyl-Propane Thiosulfonate (PTSO) Inhibits Colorectal Tumor Progression in a Humanized Mouse Model
Nutrients · 2025
DOI: 10.3390/nu17182993 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2025. Verfasst von María Jesús Rodríguez-Sojo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, 18071 Granada, Spain. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Leukocytes, Mononuclear. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Junta de Andalucía, Instituto de Salud Carlos III, European Union.
Abstract (Originalsprache)
Background/Objectives: Colorectal cancer (CRC) remains a major global health challenge and current therapies are not always effective. In addition, certain immune cell populations, such as myeloid-derived suppressor cells (MDSCs), pose a significant barrier to immune-based treatments. Some phytochemicals, particularly compounds derived from Allium spp. like Propyl-Propane Thiosulfonate (PTSO), have shown strong immunomodulatory potential in digestive disorders. This study aims to investigate the capacity of PTSO to modulate immune responses and affect tumor progression in CRC models, in vitro and in vivo, with a focus on the immune cell populations that comprise the tumor microenvironment.
Methods
Human peripheral blood mononuclear cells (hPBMCs) were incubated with PTSO (25 μM for 48 h) and characterized by flow cytometry. These cells (1 × 106) were then injected into NOD scid gamma (NSG) immunodeficient mice, which were simultaneously induced to develop a subcutaneous tumor by injection of HCT116 enriched cancer stem cells (CSCs) colonospheres (60,000 cells/mouse).
Results
PTSO reduced MDSC populations, specifically, it significantly reduced monocytic (M-MDSCs, Control: 7.27 ± 0.53% vs. PTSO: 4.70 ± 2.39%; p = 0.0458) and polymorphonuclear (PMN-MDSCs, Control: 5.28 ± 0.99% vs. PTSO: 3.41 ± 1.58%; p = 0.0385) MDSCs. In parallel, PTSO increased T cell subpopulations, particularly interferon gamma (IFNG)-producing cytotoxic CD8+ T cells (Control: 9.52 ± 2.06% vs. PTSO: 15.04 ± 5.01%; p = 0.0685). In the humanized tumor xenograft mouse, the administration of PTSO-pretreated hPBMCs led to a significant reduction in tumor size (Control: 1.43 ± 0.82 cm3 vs. PTSO: 0.44 ± 0.35 cm3; p = 0.0068), accompanied by increased infiltration of CD4+ T lymphocytes and Natural Killer (NK) cells and downregulation of immunosuppressive genes. These effects resulted in a reduction in cancer cell proliferation and invasiveness.
Conclusions
The dual effect of PTSO on immune cell populations, reducing immunosuppressive myeloid cells and enhancing effector T lymphocyte and NK cell responses, resulted in an anti-tumor effect, highlighting this bioactive compound as a promising adjuvant in CRC immunotherapy and opening avenues for future research combining immunotherapy with PTSO in alternative models to optimize dosing and enhance translational potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, 18071 Granada, Spain.
- Instituto de Investigación Biosanitaria ibs.GRANADA, 18012 Granada, Spain.
- Digestive System Service, Virgen de las Nieves University Hospital, 18014 Granada, Spain.
- Department of Biochemistry and Molecular Biology II, Faculty of Pharmacy, Campus de Cartuja s/n, University of Granada, 18016 Granada, Spain.
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain.
- Excellence Research Unit "Modeling Nature" (MNat), Centre for Biomedical Research (CIBM), University of Granada, 18071 Granada, Spain.
ORCID-Profile: María Jesús Rodríguez-Sojo, Luckman Gbati, Jose Alberto Molina-Tijeras, Teresa Vezza, Carmen Griñán-Lisón, Juan Antonio Marchal, Alberto Baños, María José Rodríguez-Sánchez, Jorge García-García, Antonio Jesús Ruiz-Malagón, Julio Gálvez, María Elena Rodríguez-Cabezas, Alba Rodríguez-Nogales
Förderung
- Junta de Andalucía
- Instituto de Salud Carlos III
- European Union
- Junta de Andalucia (CTS164) (Spain) and Fondo Europeo de Desarrollo Regional (FEDER)
- University of Granada Library
Zitieren
APA
Rodríguez-Sojo, M. J., Gbati, L., Molina-Tijeras, J. A., Ho-Plágaro, A., Vezza, T., López-Escánez, L., Griñán-Lisón, C., Marchal, J. A., Baños, A., Rodríguez-Sánchez, M. J., García-García, J., Ruiz-Malagón, A. J., Gálvez, J., Rodríguez-Cabezas, M. E., & Rodríguez-Nogales, A. (2025). Modulation of Human Immune Cells by Propyl-Propane Thiosulfonate (PTSO) Inhibits Colorectal Tumor Progression in a Humanized Mouse Model. Nutrients. https://doi.org/10.3390/nu17182993
Vancouver
Rodríguez-Sojo MJ, Gbati L, Molina-Tijeras JA, Ho-Plágaro A, Vezza T, López-Escánez L, et al. Modulation of Human Immune Cells by Propyl-Propane Thiosulfonate (PTSO) Inhibits Colorectal Tumor Progression in a Humanized Mouse Model. Nutrients. 2025. doi:10.3390/nu17182993
BibTeX
@article{RodrguezSojo2025,
author = {Rodríguez-Sojo, María Jesús and Gbati, Luckman and Molina-Tijeras, Jose Alberto and Ho-Plágaro, Ailec and Vezza, Teresa and López-Escánez, Laura and Griñán-Lisón, Carmen and Marchal, Juan Antonio and Baños, Alberto and Rodríguez-Sánchez, María José and García-García, Jorge and Ruiz-Malagón, Antonio Jesús and Gálvez, Julio and Rodríguez-Cabezas, María Elena and Rodríguez-Nogales, Alba},
title = {Modulation of Human Immune Cells by Propyl-Propane Thiosulfonate (PTSO) Inhibits Colorectal Tumor Progression in a Humanized Mouse Model},
journal = {Nutrients},
year = {2025},
doi = {10.3390/nu17182993}
}
EUVIMED